Cargando…
Live vaccines—a short‐cut to cancer viro‐immunotherapy
Tumour immunotherapies have been a breakthrough in clinical oncology but only a few patients benefit from this progress. Additional interventions that sensitize immunologically cold tumours for the administration of checkpoint modifiers are urgently needed. In this issue of EMBO Molecular Medicine,...
Autores principales: | Wirth, Thomas C, Niemann, Julia, Kühnel, Florian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6949510/ https://www.ncbi.nlm.nih.gov/pubmed/31746105 http://dx.doi.org/10.15252/emmm.201911496 |
Ejemplares similares
-
Rewiring cancer cell death to enhance oncolytic viro-immunotherapy
por: Workenhe, Samuel T, et al.
Publicado: (2013) -
Cancer immunotherapy in routine cost‐effective cancer care?
por: Feldmann, Sir Marc
Publicado: (2018) -
Living a longer life: unique lessons from the naked mole‐rat blood system
por: Andersson, Rebecca, et al.
Publicado: (2022) -
Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas
por: Zeng, Jiayi, et al.
Publicado: (2021) -
Immunogenic cell death: The cornerstone of oncolytic viro-immunotherapy
por: Palanivelu, Lalitha, et al.
Publicado: (2023)